Search

Your search keyword '"Oliver, Thomas"' showing total 15 results
Start Over Author "Oliver, Thomas" Journal journal of clinical oncology
15 results on '"Oliver, Thomas"'

1. Reply to X. Luo et al

Author

Giri, Veda N., primary, Oliver, Thomas K., additional, Rumble, R. Bryan, additional, and Geisel, Rachel L., additional

Published
2023
Full Text
View/download PDF

3. Clinical impact of MAPK pathway alterations in advanced biliary tract cancer (BTC): SCRUM-Japan GOZILA and COLOMATE international collaboration.

Author

Takahashi, Hideaki, primary, Caughey, Bennett Adam, additional, Umemoto, Kumiko, additional, Green, Michelle, additional, Nakamura, Yoshiaki, additional, Datto, Michael, additional, Ueno, Makoto, additional, Walden, Daniel, additional, Esaki, Taito, additional, Oliver, Thomas, additional, Komatsu, Yoshito, additional, Mizuno, Nobumasa, additional, Oki, Eiji, additional, Taniguchi, Hiroya, additional, Bando, Hideaki, additional, Morizane, Chigusa, additional, Yoshino, Takayuki, additional, Strickler, John H, additional, Ikeda, Masafumi, additional, and Bekaii-Saab, Tanios S., additional

Published
2022
Full Text
View/download PDF

6. Safe Handling of Hazardous Drugs: ASCO Standards

Author

Celano, Paul, primary, Fausel, Christopher A., additional, Kennedy, Erin B., additional, Miller, Tim M., additional, Oliver, Thomas K., additional, Page, Ray, additional, Ward, Jeffery C., additional, and Zon, Robin T., additional

Published
2019
Full Text
View/download PDF

7. Preclinical evaluation of AMG 160, a next-generation bispecific T cell engager (BiTE) targeting the prostate-specific membrane antigen PSMA for metastatic castration-resistant prostate cancer (mCRPC)

Author

Peter Kufer, Petra Deegen, Virginie Nägele, Angela Coxon, Benno Rattel, Pamela Bogner, Oliver Thomas, Katja Matthes, Tobias Raum, Joachim Wahl, Shyun Li, Mike Liao, Doris Rau, and Julie M. Bailis

Subjects
Cancer Research, Chemotherapy, business.industry, medicine.medical_treatment, T cell, Disease, Castration resistant, medicine.disease, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Glutamate carboxypeptidase II, medicine, Cancer research, Off the shelf, business, 030215 immunology, Hormone
Abstract

301 Background: mCRPC is a disease of high unmet medical need, especially for patients who fail novel hormonal therapies and chemotherapy. BiTE molecules provide an off the shelf therapy that activates a patient’s own immune system and redirects T cells to kill tumor cells. The BiTE mechanism of action is distinct from other immunotherapies and may unlock immune response in mCRPC. PSMA is a compelling BiTE target that is highly expressed on PCa compared to normal tissue and has increased expression in mCRPC. Methods: AMG 160 is a fully human, half-life extended (HLE) BiTE that targets PSMA on tumor cells and CD3 on T cells. AMG 160 comprises two tandem single chain variable fragments fused to an Fc domain. Results: AMG 160 binds human and non-human primate (NHP) PSMA and CD3, leading to T cell activation and proliferation and cytokine production. AMG 160 redirects T cells to kill PSMA-positive cancer cell lines in vitro, including those with low PSMA levels or androgen-independent signaling. Weekly dosing of AMG 160 induces significant antitumor activity in established PCa xenograft model. The pharmacokinetics (PK) and pharmacodynamics of AMG 160 were tested in NHP. AMG 160 treatment led to BiTE target engagement in vivo, including transient T cell activation and cytokine release in blood, and mixed cellular infiltrates in multiple organs known to express PSMA. AMG 160 treatment was well tolerated. Cytokine release associated with the first dose could be attenuated using a step dose regimen. The half-life of AMG 160 in NHP was about one week. Based on allometric scaling, the PK profile of AMG 160 may be projected to enable dosing every other week in humans. Conclusions: AMG 160 is a potent HLE BiTE with specificity for PSMA-positive tumor cells. A Phase 1 study is planned to evaluate the safety and efficacy of AMG 160 in patients with mCRPC.

Published
2019

8. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review

Author

Merker, Jason D., primary, Oxnard, Geoffrey R., additional, Compton, Carolyn, additional, Diehn, Maximilian, additional, Hurley, Patricia, additional, Lazar, Alexander J., additional, Lindeman, Neal, additional, Lockwood, Christina M., additional, Rai, Alex J., additional, Schilsky, Richard L., additional, Tsimberidou, Apostolia M., additional, Vasalos, Patricia, additional, Billman, Brooke L., additional, Oliver, Thomas K., additional, Bruinooge, Suanna S., additional, Hayes, Daniel F., additional, and Turner, Nicholas C., additional

Published
2018
Full Text
View/download PDF

10. Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion

Author

Virgo, Katherine S., primary, Basch, Ethan, additional, Loblaw, D. Andrew, additional, Oliver, Thomas K., additional, Rumble, R. Bryan, additional, Carducci, Michael A., additional, Nordquist, Luke, additional, Taplin, Mary-Ellen, additional, Winquist, Eric, additional, and Singer, Eric A., additional

Published
2017
Full Text
View/download PDF

11. Innovations in American Society of Clinical Oncology Practice Guideline Development

Author

Somerfield, Mark R., primary, Bohlke, Kari, additional, Browman, George P., additional, Denduluri, Neelima, additional, Einhaus, Kaitlin, additional, Hayes, Daniel F., additional, Khorana, Alok A., additional, Miller, Robert S., additional, Mohile, Supriya G., additional, Oliver, Thomas K., additional, Ortiz, Eduardo, additional, and Lyman, Gary H., additional

Published
2016
Full Text
View/download PDF

12. Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline

Author

Basch, Ethan, primary, Loblaw, D. Andrew, additional, Oliver, Thomas K., additional, Carducci, Michael, additional, Chen, Ronald C., additional, Frame, James N., additional, Garrels, Kristina, additional, Hotte, Sebastien, additional, Kattan, Michael W., additional, Raghavan, Derek, additional, Saad, Fred, additional, Taplin, Mary-Ellen, additional, Walker-Dilks, Cindy, additional, Williams, James, additional, Winquist, Eric, additional, Bennett, Charles L., additional, Wootton, Ted, additional, Rumble, R. Bryan, additional, Dusetzina, Stacie B., additional, and Virgo, Katherine S., additional

Published
2014
Full Text
View/download PDF

15. Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.

Author

Basch, Ethan, Loblaw, D Andrew, Oliver, Thomas K, Carducci, Michael, Chen, Ronald C, Frame, James N, Garrels, Kristina, Hotte, Sebastien, Kattan, Michael W, Raghavan, Derek, Saad, Fred, Taplin, Mary-Ellen, Walker-Dilks, Cindy, Williams, James, Winquist, Eric, Bennett, Charles L, Wootton, Ted, Rumble, R Bryan, Dusetzina, Stacie B, and Virgo, Katherine S

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results